Prosecution Insights
Last updated: May 29, 2026
Application No. 18/286,181

AN ELASTOMERIC ARTICLE

Non-Final OA §103
Filed
Oct 09, 2023
Priority
Apr 09, 2021 — MA PI2021001968 +1 more
Examiner
HAGOPIAN, CASEY SHEA
Art Unit
1617
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Matang Manufacturing Sdn Bhd
OA Round
1 (Non-Final)
54%
Grant Probability
Moderate
1-2
OA Rounds
8m
Est. Remaining
87%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allowance Rate
304 granted / 559 resolved
-5.6% vs TC avg
Strong +33% interview lift
Without
With
+32.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
33 currently pending
Career history
610
Total Applications
across all art units

Statute-Specific Performance

§101
0.3%
-39.7% vs TC avg
§103
59.4%
+19.4% vs TC avg
§102
5.5%
-34.5% vs TC avg
§112
10.5%
-29.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 559 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-17 are pending in the application. Election/Restrictions Applicant’s election without traverse of Group I (claims 1 and 3-12) in the reply filed on 2/17/2026 is acknowledged. Claims 2 and 13-17 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Accordingly, claims 1 and 3-12 are currently under examination. Information Disclosure Statement The IDS dated 2/12/2024 has been considered. A signed copy is enclosed herewith. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-4, 6 and 10-12 are rejected under 35 U.S.C. 103 as being unpatentable over Hamann (US 2004/0091557 A1, May 13, 2004, hereafter as “Hamann” in view of Silberstein et al. (WO 2017/191629 A1, Nov. 9, 2017, hereafter as “Silberstein”) and Liu (CN 111450023 A, Jul. 28, 2020, machine translation, hereafter as “Liu”). The claimed invention is drawn to an elastomeric article (10) comprising: a substrate body (11) defining an inner surface (12) proximal to skin of a user and an outer surface (13) distal to the skin of the user, the substrate body (11) comprises an elastomer; an intermediate coating (15) overlying at least a portion of the inner surface (12), the intermediate coating (15) comprises a therapeutic agent; and an inner coating (14) overlying at least a portion of the intermediate coating (15), wherein the inner coating (14) comprises an extract of soapnuts for preserving the therapeutic agent. Regarding instant claims 1, 3, 4 and 12, Hamman teaches elastomeric articles such as gloves having multiple layers (Abstract; [0010]; Figures 4, 6 and 22). In a particular embodiment, Hamman teaches an elastomeric glove having an elastomeric substrate layer, an intermediary layer on the substrate comprising a botanical extract, preferably Aloe vera, and a coating surface layer on the intermediary layer containing a non-Aloe vera material ([0156]; Fig. 9). It is noted that a glove is a substrate that has an inner surface proximal to the skin of a user and an outer surface distal to the skin of the user. Hamman also teaches that typically a 5% to 20% solution (water and/or ethanol) of the non-Aloe vera botanical extract is applied, but may range from 1% to 50% solution (based on a 100:1 powder of non-Aloe vera botanical extract) ([0148]). Hamman is silent to an extract of soapnuts (instant claim 1) as well as a preservative (instant claim 6). Silberstein teaches anti-bacterial compositions comprising saponins, which act as a preservative (page 2). The saponins include those derived from Sapindus mukorossi (Indian soapberry; Examples 7 and 9). Silberstein teaches that the compositions can contain between 0.01 and 2 wt% saponin (page 4, 4th paragraph). Silberstein teaches said compositions are suitable for application to the skin (page 17, 5th paragraph). Liu teaches a bath composition having skin care properties, comprising soapberry extract and Aloe vera extract in a ratio of 1:1 (Embodiment/Example 2). The references are all drawn to compositions for application to the skin, thus, it would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to include an extract of soapnuts, a known preservative, in the non-Aloe vera coating surface layer of Hamman, as suggested by Silberstein and Liu, with a reasonable expectation of success. A skilled artisan would have been motivated to do so because the prior art teaches that saponins derived from Indian soapberry have antibacterial and preservative properties and the combination of Aloe vera and soapnut extracts has been demonstrated as an effective skin care composition. Regarding instant claim 10, The references teach the elements discussed above. Hamman teaches that typically a 5% to 20% solution (water and/or ethanol) of the non-Aloe vera botanical extract is applied, but may range from 1% to 50% solution (based on a 100:1 powder of non-Aloe vera botanical extract) ([0148]). Silberstein teaches that the compositions can contain between 0.01 and 2 wt% saponin (page 4, 4th paragraph). While the references do not explicitly teaches the inner coating having 20-30% by volume of 1% (w/v) soapnuts extract, the references teach the general conditions of the claim and it would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to optimize the amount of extract of soapnuts by way of routine optimization with a reasonable expectation of success. MPEP 2144.05(II)(A) states, “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation”. A skilled artisan would have been motivated to do so because it is the normal desire of scientists or artisans to improve upon what is already generally known and determine where in a disclosed set of percentage ranges is the optimum combination of percentages (MPEP 2144.05). Regarding instant claim 11, The references teach the elements discussed above. Hamman also teaches the particular elastomer materials, natural rubber, a synthetic polyisoprene, a chloroprene, a polyurethane (PU), a polyvinyl chloride (PVC), a styrene butadiene styrene (SBS), a styrene isoprene styrene (SIS), a silicone, a butadiene methylmethacrylate, an acrylonitrile, a styrene ethylene butylene styrene (SEBS), an acrylate-based hydrogel ([0007]). Thus, the combined teachings of Hamman, Silberstein and Liu render the instant claims prima facie obvious. Claims 5, 8 and 9 are rejected under 35 U.S.C. 103 as being unpatentable over Hamann (US 2004/0091557 A1, May 13, 2004, hereafter as “Hamann” in view of Silberstein et al. (WO 2017/191629 A1, Nov. 9, 2017, hereafter as “Silberstein”) and Liu (CN 111450023 A, Jul. 28, 2020, machine translation, hereafter as “Liu”), as applied claims 1 and 3 above, and further in view of Foo et al. (WO 2018/119491 A1, Jul. 5, 2018, hereafter as “Foo”). The claimed invention is described above. Hamman, Silberstein and Liu teach the elements discussed above. Hamman, Silberstein and Liu are silent to the combination of Aloe vera and ginseng (instant claim 5). Foo teaches elastomeric articles such as gloves comprising a coating having skin care properties (abstract; page 1, lines 4-7). Foo teaches that the coatings can contain skin care components such as Aloe vera and ginseng, and general amounts thereof (page 12, last paragraph - page 13, 2nd paragraph). The references are all drawn to compositions for application to the skin, thus, it would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to include ginseng in a coating layer of Hamman/Silberstein/Liu, as suggested by Foo, with a reasonable expectation of success. A skilled artisan would have been motivated to do so because the Foo teaches that ginseng and Aloe vera are suitable skin care components of a coating composition for an elastomeric article such as glove. MPEP 2144.06(I) states, “It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art”. Hamman, Silberstein and Liu are silent to a first intermediate coating comprising Aloe vera and a second intermediate coating comprising ginseng (instant claim 8). The references are all drawn to compositions for application to the skin, thus, it would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to include ginseng in a first intermediate coating layer and Aloe vera in a second intermediate coating layer of Hamman/Silberstein/Liu/Foo with a reasonable expectation of success. A skilled artisan would have been motivated to do so because Hamman teaches various multi-layer coating embodiments, wherein the surface coating layer is a non-Aloe coating layer and optimizing the number of layers and the arrangement of active ingredients in the layers by routine experimentation is within the normal desire of scientists or artisans to improve upon what is already generally known. Hamman, Silberstein and Liu are silent to the claimed percentage of Aloe vera and ginseng (instant claim 9). The references are all drawn to compositions for application to the skin, thus, it would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to optimize the amounts of ginseng and Aloe vera in Hamman/Silberstein/Liu/Foo by way of routine experimentation with a reasonable expectation of success. A skilled artisan would have been motivated to do so because the references teach various amounts of the active ingredients and it is within the normal desire of scientists or artisans to improve upon what is already generally known. Thus, the combined teachings of Hamman, Silberstein, Liu and Foo render the instant claims prima facie obvious. Claims 6 and 7 are rejected under 35 U.S.C. 103 as being unpatentable over Hamann (US 2004/0091557 A1, May 13, 2004, hereafter as “Hamann” in view of Silberstein et al. (WO 2017/191629 A1, Nov. 9, 2017, hereafter as “Silberstein”) and Liu (CN 111450023 A, Jul. 28, 2020, machine translation, hereafter as “Liu”), as applied claim 1 above, and further in view of Leong (US 2002/0114825 A1 Aug. 22, 2002, hereafter as “Leong”). The claimed invention is described above. Hamman, Silberstein and Liu teach the elements discussed above. Hamman, Silberstein and Liu are silent to the particular preservatives, sodium benzoate or potassium benzoate. Leong teaches an elastomeric article such as a glove comprising an Aloe vera coating (Abstract; [0001]). Said coating comprising Aloe vera extract and sodium benzoate as a preservative ([0011] and [0022]). The references are all drawn to compositions for application to the skin, thus, it would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to include the particular preservative, sodium benzoate in the invention of Hamman/Silberstein/Liu, as suggested by Leong, with a reasonable expectation of success. A skilled artisan would have been motivated to do so because Leong teaches that sodium benzoate is an effective preservative in a skin care composition comprising Aloe vera for coating an elastomeric article such as a glove. Thus, the combined teachings of Hamman, Silberstein, Liu and Leong render the instant claims prima facie obvious. Conclusion All claims have been rejected; no claims are allowed. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to CASEY HAGOPIAN whose telephone number is (571)272-6097. The examiner can normally be reached on M-F 9:00 am - 5:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sue Liu can be reached on 571-272-5539. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CASEY S HAGOPIAN/Examiner, Art Unit 1617
Read full office action

Prosecution Timeline

Oct 09, 2023
Application Filed
Mar 27, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12629448
PREPARATION METHOD FOR THREE-DIMENSIONAL GELATIN SCAFFOLD WITH INTERCONNECTED PORES AND APPLICATION THEREOF
1y 5m to grant Granted May 19, 2026
Patent 12605346
COMPOSITION CONTAINING CURCUMIN COMPOUND, AND METHOD FOR PRODUCING SAME
3y 8m to grant Granted Apr 21, 2026
Patent 12569597
METHODS FOR FORMING STENTS MODIFIED WITH MATERIAL COMPRISING AMNION TISSUE
2y 5m to grant Granted Mar 10, 2026
Patent 12551414
Systems And Methods For Delivering Active Agents
3y 9m to grant Granted Feb 17, 2026
Patent 12539213
GROWTH FACTOR TRANSDUCED CELL-LOADED CERAMIC SCAFFOLD FOR BONE REGENERATION AND REPAIR
1y 7m to grant Granted Feb 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
54%
Grant Probability
87%
With Interview (+32.7%)
3y 3m (~8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 559 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month